SCHEMBL9890692

SCHEMBL9890692

COC(=O)C(O)c1ccc(F)cc1-c1cc(Cl)cc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 12/20 0.44
CHRM2 P08172 1/20 0.42
CHRM1 P11229 1/20 0.42
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
APP P05067 3/20 0.40
NR3C2 P08235 3/20 0.40
CTSA P10619 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890697 0.89 PSEN1 (0.44) CHRM3CHRM2CHRM1PSEN1PSEN2
SCHEMBL9890689 0.83 CHRM3 (0.42) CHRM3CHRM2CHRM1NR3C2
SCHEMBL9890690 0.82 CHRM3 (0.43) CHRM3NR3C2
SCHEMBL2393512 0.82 APP (0.47) CHRM3CHRM2CHRM1APPCTSA
SCHEMBL9890691 0.82 KCNA5 (0.46) CHRM3APPCTSA
SCHEMBL9890693 0.77 NR3C2 (0.44) CHRM3CHRM2CHRM1PSEN1PSEN2
SCHEMBL9890699 0.77 CTSA (0.41) CHRM3PSEN1PSEN2APH1BNCSTN
SCHEMBL8595608 0.76 CES2 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6400373 0.76 CES2 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL10094434 0.75 APP (0.41) CHRM3CHRM2CHRM1PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CHRM3 298/4885CHRM2 159/4885CHRM1 340/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CHRM3 298/4885CHRM2 159/4885CHRM1 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.